Equities analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to announce sales of $3.70 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Aclaris Therapeutics’ earnings, with the lowest sales estimate coming in at $2.52 million and the highest estimate coming in at $4.87 million. Aclaris Therapeutics reported sales of $680,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 444.1%. The business is scheduled to announce its next earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Aclaris Therapeutics will report full-year sales of $14.09 million for the current year, with estimates ranging from $10.59 million to $17.59 million. For the next year, analysts expect that the business will report sales of $42.83 million, with estimates ranging from $36.16 million to $49.50 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.04. The business had revenue of $3.68 million during the quarter, compared to analyst estimates of $2.76 million. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%.
Shares of ACRS stock traded up $0.28 during trading hours on Monday, reaching $13.58. The company had a trading volume of 205,116 shares, compared to its average volume of 267,547. The firm has a market capitalization of $449.84 million, a PE ratio of -5.43 and a beta of 1.22. Aclaris Therapeutics has a 12-month low of $12.84 and a 12-month high of $27.20.
In other Aclaris Therapeutics news, Director Stephen A. Tullman acquired 7,100 shares of the stock in a transaction that occurred on Thursday, October 4th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $99,400.00. Following the completion of the transaction, the director now owns 177,457 shares of the company’s stock, valued at approximately $2,484,398. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen A. Tullman acquired 6,600 shares of the stock in a transaction that occurred on Thursday, August 23rd. The stock was acquired at an average price of $15.00 per share, with a total value of $99,000.00. Following the completion of the transaction, the director now directly owns 170,357 shares of the company’s stock, valued at approximately $2,555,355. The disclosure for this purchase can be found here. Insiders bought 19,950 shares of company stock valued at $298,213 over the last 90 days. Company insiders own 17.00% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its position in Aclaris Therapeutics by 561.0% in the first quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 5,531 shares during the period. Summit Trail Advisors LLC grew its position in Aclaris Therapeutics by 5,594.3% in the first quarter. Summit Trail Advisors LLC now owns 135,239 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 132,864 shares during the period. Cubist Systematic Strategies LLC grew its position in Aclaris Therapeutics by 518.4% in the first quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 7,009 shares during the period. Bank of Montreal Can purchased a new position in Aclaris Therapeutics in the second quarter worth approximately $159,000. Finally, Granite Investment Partners LLC purchased a new position in Aclaris Therapeutics in the second quarter worth approximately $164,000. Institutional investors own 99.75% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Recommended Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.